Rodrigo Ruiz Soto
Chief Tech/Sci/R&D Officer at DECIPHERA PHARMACEUTICALS, INC.
Profile
Rodrigo Ruiz Soto is currently working as the Senior Vice President-Clinical Development at Deciphera Pharmaceuticals, Inc. He previously worked as the Medical Director at Sanofi, Inc. and as the Senior Director-Medical at ImmunoGen, Inc. Dr. Ruiz Soto holds a doctorate degree from Universidad Nacional Autónoma de México.
Rodrigo Ruiz Soto active positions
| Companies | Position | Start |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2016-12-31 |
Former positions of Rodrigo Ruiz Soto
| Companies | Position | End |
|---|---|---|
| IMMUNOGEN, INC. | Chief Tech/Sci/R&D Officer | - |
Sanofi, Inc.
 Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a company based in New York, NY. | Chief Tech/Sci/R&D Officer | - |
Training of Rodrigo Ruiz Soto
| Universidad Nacional Autónoma de México | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Deciphera Pharmaceuticals, Inc.
 Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
Sanofi, Inc.
Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a company based in New York, NY. | Retail Trade |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Rodrigo Ruiz Soto
